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Abstract
NPRL-Z-1 is a 4b-[(40-benzamido)-amino]-49-O-demethyl-epipodophyllotoxin derivative. Previous reports have shown that
NPRL-Z-1 possesses anticancer activity. Here NPRL-Z-1 displayed cytotoxic effects against four human cancer cell lines (HCT
116, A549, ACHN, and A498) and exhibited potent activity in A498 human renal carcinoma cells, with an IC50 value of
2.38 mM via the MTT assay. We also found that NPRL-Z-1 induced cell cycle arrest in G1-phase and detected DNA double-
strand breaks in A498 cells. NPRL-Z-1 induced ataxia telangiectasia-mutated (ATM) protein kinase phosphorylation at serine
1981, leading to the activation of DNA damage signaling pathways, including Chk2, histone H2AX, and p53/p21. By ICE
assay, the data suggested that NPRL-Z-1 acted on and stabilized the topoisomerase II (TOP2)–DNA complex, leading to
TOP2cc formation. NPRL-Z-1-induced DNA damage signaling and apoptotic death was also reversed by TOP2a or TOP2b
knockdown. In addition, NPRL-Z-1 inhibited the Akt signaling pathway and induced reactive oxygen species (ROS)
generation. These results demonstrated that NPRL-Z-1 appeared to be a novel TOP2 poison and ROS generator. Thus, NPRL-
Z-1 may present a significant potential anticancer candidate against renal carcinoma.
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Introduction
Cancer is a leading cause of death worldwide. Many anticancer
agents that target DNA are currently most effective clinically and
lead to significant improvements in the survival of cancer patients
when used along with drugs with different mechanisms [1]. DNA
topoisomerases are recognized as important targets in anticancer
drug discovery [2–5]; approximately 50% of current antitumor
treatment regimens include at least one drug that acts as a
topoisomerase inhibitor [6,7].
Topoisomerases are essential nuclear enzymes that are involved
in DNA supercoiling regulation and play key roles in transcription,
replication, and chromosome segregation [8–11]. Two major
classes of topoisomerases (types I and II) are distinguished by the
number of DNA strands that they cleave and the mechanism by
which they alter the topological properties of DNA [12,13].
Topoisomerase I catalyzes supercoiled DNA unwinding by
transiently creating a break in a single-stranded DNA (ssDNA)
[14], whereas TOP2 creates DNA double-stranded breaks (DSBs)
to allow the passage of a second double-stranded DNA through
the transiently broken duplex [15]. There are two TOP2 isoforms,
TOP2a (170 kDa) and TOP2b (180 kDa), in human cells. TOP2a
levels peak at the G2/M phase and high levels of the same are
expressed in proliferating tumor cells, whereas TOP2b levels do
not significantly alter during cell cycle and is often present in both
proliferating and differentiated cells [16]. Currently available
TOP2-targeted drugs are classified as TOP2 poisons and catalytic
inhibitors [17]. TOP2 poisons, such as etoposide (VP-16),
doxorubicin, anthracyclines, ciprofloxacin, and amsacrine (m-
AMSA), increase and stabilize covalent, TOP2-cleaved, DNA
complexes, and thus block religation, enzymatic release, and,
ultimately, induce apoptosis [18,19]. Catalytic inhibitors inhibit
the overall catalytic activity of TOP2, preferring not to stabilize
the covalent TOP2–DNA cleavage complexes [20,21]. In contrast,
most TOP2 poisons frequently induce multidrug resistance and
have dose-limiting toxicities, resulting in treatment failure after
initial effective therapy [22,23]. Moreover, they may trigger
chromosomal translocations that can lead to a specific leukemia
type by inducing DNA strand breaks [21,24]. Therefore,
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considerable cancer research is the current focus to develop novel
TOP2-targeted drugs in order to improve the current situation.
NPRL-Z-1, 49-O-Demethyl-4b-[40(benzyl L-alanyl-N-carbonyl)-
anilino]-4 -desoxy-podophyllotoxin, is synthesized by Dr. Lee et al.
(Natural Products Laboratory, University of North Carolina,
Chapel Hill, NC, USA), and designed to enhance TOP2
inhibition, overcome drug resistance, and modulate water
solubility of etoposide analogues by extending the bulky substit-
uent at C7 [25] (It was compound 14 in the cited article). Here
NPRL-Z-1 mechanisms associated with cell apoptosis in human
renal cell carcinoma (RCC) A498 cells were first investigated,
which showed that NPRL-Z-1 had better cytotoxicity against
A498 cancer cells than etoposide and induced DNA damage
through TOP2 inhibition. The data suggested that NPRL-Z-1 is a
novel TOP2 poison and provides an alternative mechanism that
can be exploited in RCC therapy.
Materials and Methods
Reagents and chemicals
NPRL-Z-1 was synthesized by Dr. Lee et al. (Natural Products
Laboratory, University of North Carolina, Chapel Hill, NC,
USA). Minimum Essential Medium (MEM), RPMI 1640 medium,
fetal bovine serum (FBS), penicillin, and streptomycin were
obtained from Gibco BRL Life Technologies (Grand Island,
NY). EGTA, EDTA, leupeptin, dithiothreitol, phenylmethylsulfo-
nyl fluoride (PMSF), propidium iodide (PI), dimethyl sulfoxide
(DMSO), MTT (3-[4,5]-2,5-diphenyltetrazolium bromide), 49-6-
diamidino-2-phenylindole (DAPI), N-acetyl-L-cysteine (NAC) and
etoposide were obtained from Sigma (St Louis, MO). Antibodies
to various proteins were obtained from the following sources: anti-
mouse and anti-rabbit IgGs, poly-ADP-ribosepolymerase (PARP),
cyclin D1, cyclin E, cdk2, cdk4, p27, and TOP2b antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA);
E2F-1, p21, p-Histone H2AX (Ser 139), p-ATM (Ser 1981), p-
chk2 (Thr 68), p53 (Ser 15), p53 (Ser 20), cleaved caspase-3,
caspase-9, and -8 were purchased from Cell Signaling Technology
(Boston, MA); caspase-3 was purchased from Imgenex (San Diego,
CA); p53, Retinoblastoma protein (Rb), TOP1 and TOP2a were
purchased from BD Biosciences (San Diego, CA); actin was
purchased from CHEMICON (Temecula, CA).
Cell culture
Human cancer cell lines HCT 116, A549, ACHN, and A498
were purchased from the American Type Culture Collection
(Manassas, VA). HCT 116, A549, and ACHN were cultured in
RPMI 1640 medium and A498 cells were cultured in Minimum
Essential Medium. Both media were supplemented with 10% FBS
(v/v) and penicillin (100 U/mL)/streptomycin (100 mg/mL).
Cultures were maintained in a humidified incubator at 37uC in
5% CO2/95% air.
MTT assay
Cell viability was determined using MTT assay. In 96-well,
5,000 cells were seeded in complete media with presence or
absence of NPRL-Z-1 and described in the previous study. Briefly,
100 ml MTT solution (0.5 mg/mL in phosphate-buffered saline;
PBS) was added to each well. After 1 h incubation at 37uC, MTT
solution was removed and DMSO was added to dissolve dye.
Absorbance at 550 nm was measured using a microplate reader
(Thermo Multiskan GO, Waltham, MA), using RPMI or MEN
medium as a blank.
In situ labeling of apoptotic cells
NPRL-Z-1-induced A498 cell apoptosis was detected using the
terminal deoxynucleotidyl transferase-mediated nick-end labeling
(TUNEL) staining assay. Briefly, cells were cultured in chamber
slides for 24 h and treated with 10 mM NPRL-Z-1. After a 24 h
treatment, A498 cells were washed twice with PBS and fixed for
10 min using ice-cold 1% paraformaldehyde. Staining was
performed according to the TUNEL staining protocol provided
by Promega Corporation (Madison, WI). Finally, photomicro-
graphs of the TUNEL-stained cells were observed and photo-
graphed using Axioplan 2 fluorescence microscope (Carl Zeiss,
Jena, Germany) equipped with a CCD camera (Nikon, Japan) at
206magnification. Data were analyzed by AxioVision software.
Cell death detection assay
NPRL-Z-1-induced apoptotic death was assessed using the Cell
Death Detection ELISAPLUS kit (Roche Diagnostics, Indianapolis,
IN), which was designed for quantitative in vitro detection of
mono- and oligonucleosomal DNA fragmentation. The manufac-
turer’s protocol was applied from Roche and data were measured
by microplate reader (Thermo Multiskan GO, Waltham, MA).
Data were calculated and compared with those of a control group.
Western blot analysis
Cells were lysed with lysis buffer as previously described and the
samples were subjected to SDS-PAGE to detect protein phos-
phorylation, expression, and cleavage [26]. Briefly, proteins (30–
60 mg) were separated by 10% polyacrylamide gel (Biored,
Philadelphia, PA) and transferred to polyvinylidene fluoride
membrane (Hoefer, Richmond, CA). Non-specific binding was
blocked with 5% non-fat milk in PBS. The blots were probed with
primary antibodies and incubated with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit antibodies. Finally, the
membranes were visualized using an enhanced chemilumines-
cence kit (VISUAL PROTEIN, Taiwan).
Flow cytometry analysis
Cells were seeded in six-well plates and treated with vehicle
(0.1% DMSO) or the test compound at various concentrations for
the indicated times, harvested by trypsinization, fixed with ice-cold
70% alcohol at 220uC overnight, centrifuged, and resuspended in
0.5 mL propidium iodide solution containing Triton X-100 (0.1%,
v/v), RNase (100 mg/mL), and propidium iodide (80 mg/mL).
DNA content was analyzed by fluorescence-activated cell sorting
with the FACScan system and CellQuest software (Becton
Dickinson, Mountain View, CA).
Comet assay
Cells were seeded in 12-well plates and treated, collected, and
resuspended in ice-cold PBS. Next, the resuspended cells were
mixed with 1.5% low-melting point agarose and loaded onto a
fully frosted slide precoated with 0.7% agarose. A coverslip was
placed on the slide, which was then submerged in prechilled lysis
solution (1% Triton X-100, 2.5 M NaCl, and 10 mM EDTA,
pH 10.5) for 1 h at 4uC. After soaking in prechilled unwinding
and electrophoresis buffer (0.3 M NaOH and 1 mM EDTA) for
20 min, the slides were subjected to electrophoresis for 15 min at
0.5 V/cm (20 mA), stained with 16 Sybr Gold (Molecular
Probes), and nuclear images were visualized and captured using
an Axioplan 2 fluorescence microscope (magnification,6400; Carl
Zeiss, Jena, Germany) equipped with a CCD camera (Optronics).
More than hundreds of cells were scored to calculate the overall
comet tail-positive cell percentage.
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Topoisomerase II relaxation assay
This assay was performed according to the manufacturer’s
protocol (TopoGEN, Port Orange, FL). Briefly, each reaction
product was incubated at 37uC for 30 min and the reaction was
stopped by adding stopping buffer. The products were analyzed by
a 1% agarose gel in TAE buffer (40 mM Tris–acetate, pH 8.0,
1 mM EDTA) and stained with 0.5 mg/mL ethidium bromide for
10 min. After destaining with distilled water, the gel was
photographed using a short-wavelength UV lamp (ChemiImager
5500; Alpha Innotech, Santa Clara, CA).
Band depletion assay
Band depletion assay was performed to verify the presence of
topoisomerase cleavage complexes that were retained on substrate
DNA after topoisomerase poison treatment. Briefly, treated cells
were lysed with SDS sample buffer (4% SDS/2%-b-mercaptoeth-
anol, 20% glycerol, and 125 mM Tris HCl, pH 6.8), resolved by
SDS-PAGE, and probed with anti-topoisomerase I/II antibodies.
In vivo complex of enzyme (ICE) assay
After treatment with DMSO, NPRL-Z-1, or etoposide for
30 min, cells were collected and lysed with 1% sarkosyl in TE
buffer (10 mM Tris–HCl pH 8.0 and 1 mM EDTA). The lysates
were passed through a 26-gauge needle five times, placed on the
top of a preformed cesium chloride step gradient (1.82, 1.72, 1.50,
and 1.37 g/mL; volume, 2 mL each) in polyallomer tubes
(Beckman Coulter, UK), and centrifuged at 20uC in a Beckman
SW41 rotor at 31,000 rpm for 24 h. Next, 1 mL of each fraction
was collected from the top of the tubes. A 100-mL aliquot of each
fraction was diluted with equal volume of 25 mM sodium
phosphate buffer (pH 6.5) and transferred to a polyvinylidene
fluoride membrane, which was pre-soaked in sodium phosphate
buffer for 15 min with a dot-blot apparatus (Biored, Philadelphia,
PA). The membrane was immunoblotted with anti-TOP2
antibodies.
Small interfering RNA transfection
Small interfering RNA (siRNA) against TOP2a, TOP2b, and
the negative control were purchased from Ambion (Austin, TX),
and the assay was performed as described previously [27]. Briefly,
A498 cells were seeded in 6-cm dishes overnight, and then
transfected with 10 ml negative control, TOP2a or TOP2b using
10 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 24 h,
the medium was replaced with growth medium and cells were
treated with 2 ml DMSO or 10 mM NPRL-Z-1 for the indicated
time.
Measurement of reactive oxygen species
Intracellular reactive oxygen species level was detected using
2,7-dichlorofluoroscein diacetate (DCFH-DA). Cells were incu-
bated in the absence or presence of the indicated agents for 0.5, 1
or 3 h. After DCFH-DA (10 mM) incubation for 30 min at 37uC,
cells were harvested for the detection of ROS accumulation using
FACScan flow cytometric analysis.
Statistical analysis
All experiments were performed at least three times. Data
expressed as mean 6 SE for the indicated number of separate
experiments. Statistical analysis of data was done with Student’s t
test. P values ,0.05 were considered significant.
Results
Effect of NPRL-Z-1 on cell viability in human cancer cells
Anticancer activity of NPRL-Z-1 was assessed in human
colorectal cancer HCT 116 cells, human non-small cell lung
carcinoma A549 cells, human renal carcinoma ACHN, and A498
cells. Cells were treated at various NPRL-Z-1 concentrations (0.3,
1, 3, 10, and 15 mM) for 48 h, and cell viability was determined
using the MTT assay (Fig. 1A). NPRL-Z-1 inhibited cell viability
in HCT116, ACHN, and A498 in a concentration-dependent
manner, with IC50 values of 9.73 mM, 7.25 mM, and 2.38 mM,
respectively. Therefore, the most potent cytotoxic effect of NPRL-
Z-1 was observed in A498 cells. However, there was no significant
decrease in cell viability among NPRL-Z-1-treated A549 cells even
at a high concentration (15 mM). In addition, etoposide inhibited
A498 cell viability in a concentration-dependent manner with an
IC50 value of 39.52 mM (Fig. 1B). Moreover, NPRL-Z-1 signifi-
cantly induced nuclear DNA fragmentation as determined by the
TUNEL assay (Fig. 1C). In light field pictures, A498 cells
appeared spindle-shaped, adhered to the surface of the culture
plate and were growth confluent after 24 h incubation. After
treatment with 10 mM NPRL-Z-1, prominent blebs on cell surface
could be observed and the cells had started shrinking and
rounding up, thus gradually detaching from the culture plate.
Thus, these results demonstrated that NPRL-Z-1 induced cancer
cell death and was 16-fold more potent than etoposide in A498
cells.
NPRL-Z-1-induced cell apoptosis accompanied by
downregulation of Akt signaling pathway in A498 cells
The effects of NPRL-Z-1 on cell apoptosis induction were
studied using a cell death detection ELISA kit. NPRL-Z-1
administration significantly triggered A498 cell apoptosis in a
concentration-dependent manner (Fig. 2A). Upon apoptosis
induction, the caspase cascade was also activated [28]. NPRL-Z-
1 decreased pro-caspase-3, -8, and -9 expression and induced
PARP and caspase-3, -8, and -9 cleavage (Fig. 2B). Furthermore,
NPRL-Z-1 displayed a strong downregulatory effect on the Akt
pathway. The phosphorylation of Akt, 4EBP1 and p70S6K were
downregulated after NPRL-Z-1 treatment (Fig. 2C and 2D).
Effect of NPRL-Z-1 on cell cycle progression
Flow cytometry and propidium iodide staining were used to
assess the effect of NPRL-Z-1 on cell cycle progression. After
NPRL-Z-1 treatment, sub-G1 cell population increased in a
concentration- and time-dependent manner (Fig. 3A and 3B).
NPRL-Z-1 also induced cell cycle arrest in the G0/G1 phase
among A498 cells.
Cell cycle progression is a complex process controlled by a
subfamily of cyclin-dependent kinases (CDKs), which are modu-
lated by several activators (cyclins) and inhibitors (Ink4 family and
Cip/Kip family) [29]. To investigate the effects of NPRL-Z-1 on
cell cycle regulatory molecules, expression levels of the indicated
proteins was assessed by western blotting. The expression levels of
p53, cyclin E and the CDK inhibitors, p21 and p27, upregulated
after NPRL-Z-1 treatment (Fig. 3C). Moreover, NPRL-Z-1
induced Cdk2 upregulation during the first 8 h and downregula-
tion during the last 6 h. However, Cdk4 and cyclin D1 expression
levels remained unchanged. Retinoblastoma (Rb) tumor suppres-
sor protein is a critical regulator of G1/S transition, which
interacts with the E2F family of cell cycle transcription factors to
repress gene transcription required for this transition [30]. The
data from this study showed that NPRL-Z-1 decreased Rb
phosphorylation and E2F-1 expression, which occurred within
NPRL-Z-1 Induces Apoptosis by Topo Inhibition
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8–24 h. Thus, these results suggested that NPRL-Z-1 induced G1
arrest in A498 cells.
Effects of NPRL-Z-1 on DNA DSBs and DNA damage
checkpoints
The comet assay was performed to determine whether NPRL-
Z-1 induced DNA damage. The results showed that NPRL-Z-1
induced chromosomal DNA strand breaks in A498 cells (Fig. 4A).
ATM phosphorylation at serine (Ser) 1981 is an indicator of DNA
damage [31]. A previous study indicated that DNA DSBs could
induce histone H2AX phosphorylation at Ser 139 [32]. NPRL-Z-1
treatment of A498 cells increased the levels of p-ATM, p-Chk2,
and p-histone H2AX (Fig. 4B). Moreover, p53 expression and
phosphorylation (Ser 15 and 20) were upregulated. These results
suggested that NPRL-Z-1 was a potent DNA-damaging agent that
triggered activation of checkpoint signaling.
Identification of TOP2 as a molecular target of NPRL-Z-1
An in vitro DNA relaxation assay was performed to investigate
whether TOP2 was involved in the NPRL-Z-1-induced DNA
Figure 1. Effects of NPRL-Z-1 on cell viability in four human cancer cell lines. (A) HCT 116, A549, ACHN, and A498 were treated with NRRL-Z-
1 at various concentrations for 48 h and analyzed using the MTT assay. (B) A498 cells were treated with vehicle or etoposide at various concentrations
for 48 h and analyzed using the MTT assay. (C) Fluorescence microscopy of untreated or NPRL-Z-1-treated A498 cells for 24 h followed by
TUNEL staining (at 206magnification). Data are expressed as the mean percentage of control 6 S.D. of three independent experiments. * p,0.05,
** p,0.01, and *** p,0.001 compared with the control group.
doi:10.1371/journal.pone.0112220.g001
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damage pathway. NPRL-Z-1 inhibited the ability of TOP2 to
convert supercoiled DNA to relaxed DNA as well as etoposide
(Fig. 5A). Furthermore, the band depletion assay was performed to
detect free intracellular topoisomerases that were not covalently
bound to cellular DNA. NPRL-Z-1 or etoposide treatment of
A498 cells caused depletion of TOP2a and TOP2b, suggesting
that NPRL-Z-1 increased intracellular accumulation of TOP2a-
and TOP2b-mediated cleavable complexes (Fig. 5B). However,
NPRL-Z-1 had no effect on TOP1–DNA complexes in A498 cells
(Fig. 5C). The TOP1 poison camptothecin was used as a positive
control. Moreover, after replacement of medium containing
NPRL-Z-1 or etoposide with fresh growth medium, TOP2a and
TOP2b expression was restored (Fig. 5D). These data clearly
Figure 2. Effects of NPRL-Z-1 treatment on cell apoptosis induction and expression of apoptosis-related proteins in A498 cells. (A)
Cells were treated with DMSO or NPRL-Z-1 at various concentrations (1, 3, 5, and 10 mM) for 24 h. Formation of cytoplasmic DNA was quantitatively
measured by cell death ELISAPLUS kit. Data are expressed as the mean percentage of control 6 S.D. of three independent experiments. * P,0.05, and
*** P,0.001 compared with the control group. A498 cells were incubated in the absence or presence of NPRL-Z-1 at various concentrations (0.3, 1, 3,
and 10 mM) for 24 h (B) and 6 h (C), and cells were harvested and prepared for detection by Western blotting. (D) Cells were treated for indicated
times, and the cell lysates were subjected to immunoblotting by using indicated antibodies.
doi:10.1371/journal.pone.0112220.g002
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showed that NPRL-Z-1 dose-dependently stabilized TOP2 in
A498 cells and the cleavable complexes were reversible.
Effect of NPRL-Z-1 on formation of covalent TOP2–DNA
complexes (TOP2cc)
Specific topoisomerase-genomic DNA cleavage complexes can
be measured using ICE assay, in which complexes are separated
from free TOP2 proteins by gradient centrifugation and detected
with specific antibodies. Free TOP2 proteins were partitioned
between fractions 1 and 4, and TOP2cc was trapped between
fractions 5 and 8. The results showed that treatment with either
NPRL-Z-1 or etoposide induced the formation of TOP2acc
(Fig. 6A) and TOP2bcc (Fig. 6B). Therefore, NPRL-Z-1 trapped
TOP2 in the form of covalent protein–DNA complexes, demon-
strating that NPRL-Z-1 is a novel TOP2 poison.
Figure 3. Effects of NPRL-Z-1 on cell cycle distribution and expression of cell cycle-related proteins in A498 cells. Cells were incubated
with (A) DMSO or various concentrations of NPRL-Z-1 for 24 h and (B) DMSO or 10 mM NPRL-Z-1 for the indicated time periods. Cell cycle phase and
cell apoptosis were determined by FACS as described in Materials and Methods. (C) A498 cells were incubated with DMSO or 10 mM NPRL-Z-1 for the
indicated time periods. After treatment, cells were harvested and lysed for detection of the indicated proteins via western blotting. Data are
expressed as the mean percentage of control 6 S.D. of three independent experiments. *, # p,0.05, and ## p,0.01 compared with the control
group.
doi:10.1371/journal.pone.0112220.g003
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TOP2 was required for NPRL-Z-1-induced cell apoptosis
in A498 cells
To determine the role of TOP2 in NPRL-Z-1-induced cell
apoptosis, we transfected A498 cells with siRNA specifically
targeted to TOP2a or TOP2b. TOP2a and TOP2b expression
was downregulated in the transfected cells (Fig. 7A and 7B). Next,
cell viability was measured using the MTT assay to assess the role
of TOP2 in NPRL-Z-1-induced cell apoptosis. The results showed
that TOP2a or TOP2b knockdown protected A498 cells from
NPRL-Z-1-induced cell death (Fig. 7C and 7D) and was also
involved in PARP cleavage and pro-caspase-3 downregulation
(Fig. 7E and 7F). Furthermore, NPRL-Z-1-induced DNA damage
checkpoints, such as p-ATM, p53, and p-histone H2AX, reduced
after TOP2a or TOP2b silencing (Fig. 7G and 7H). These data
indicated that TOP2 played a crucial role in NPRL-Z-1-induced
activation of DNA damage signaling and the apoptotic pathway.
NPRL-Z-1-induced Cell Apoptosis through Reactive
Oxygen Species Generation
It has been reported that ROS is involved in cancer cell
apoptosis induced by chemotherapeutic agents and radiotherapy
[33]. Therefore, we detected the intracellular ROS level by using
flow cytometry. As shown in Fig. 8A, a significant generation of
ROS was observed after treatment with NPRL-Z-1. Next, two
ROS scavengers (vitamin C and NAC) were studied to determine
which antioxidant could rescue the cells from NPRL-Z-1-induced
cell death. Notably, only NAC could protected from NPRL-Z-1-
induced cell death (Fig. 8B) and blocked NPRL-Z-1-induced ROS
generation (Fig. 8C). In addition, the downstream signals, caspase-
3 and PARP were restored by NAC (Fig. 8D). These results
suggested that the cell death induced by NPRL-Z-1, in the A498
cells, was also mediated by the accumulation of ROS pathway.
Discussion
RCC is the most lethal cancer among urological tumors and
there are no effective biomarkers in the prognostic or predictive
assessment till present day. In addition, approximately 30% of all
RCC patients develop metastatic lesions [34]. Because metastatic
RCC is resistant to radiation therapy and chemotherapy, novel
therapeutic treatment strategies and finding effective biomarkers
are needed urgently. Parker et al. discovered that higher
expression of TOP2a is associated with an increased risk of
cancer-related death following surgery for clinically localized clear
cell renal cell carcinoma [35]. Those tumors classified as TOP 2a
high had more aggressive pathologic features. It provides a good
reason to design the TOP 2-target therapy in RCC.
At the core of the DNA damage signaling apparatus is a pair of
related protein kinases ATM and ATR (ATM and Rad3-related)
that are activated by DNA damage. ATM senses DSBs, whereas
ATR senses ssDNA generated by processing DSBs, as well as
Figure 4. Effects of NPRL-Z-1 on DNA DSBs and DNA
checkpoint pathway. (A) A498 cells were seeded and treated with
NPRL-Z-1 or etoposide for 30 min and processed for the comet assay as
detailed in Materials and Methods. (B) A498 cells were incubated with
DMSO or 3 or 10 mM NPRL-Z-1 for the indicated time periods. After
treatment, cells were harvested and lysed for detection of the
expression of indicated protein via western blotting. N3, N10 and E25
indicated as NPRL-Z-1 3 mM, 10 mM and etoposide 25 mM, respectively.
doi:10.1371/journal.pone.0112220.g004
Figure 5. Effects of NPRL-Z-1 on TOP2 expression. (A) DNA
relaxation assay. Lane 1: 0.3 pmol of negatively supercoiled DNA
substrate and no protein; lane 2: DNA, TOP2, and DMSO; lanes 3–4:
DNA, TOP2, and NPRL-Z-1; and lane 5: DNA, TOP2 and etoposide. (B)
A498 cells were treated with NPRL-Z-1 or etoposide for 1 h to detect
the depletion of free enzymes, TOP2a and TOP2b, using the band
depletion assay. (C) A498 cells were treated with NPRL-Z-1 or
camptothecin for 1 h to detect the depletion of free enzymes, TOP1,
using the band depletion assay. (D) Restoration of depleted TOP2
expression. After treatment with NPRL-Z-1 or etoposide for 1 h, the
medium was replaced with fresh growth medium and cells were
incubated for another hour (R). Cells were then harvested and prepared
for TOP2a and TOP2b detection via western blotting. N10 and E25
indicated as NPRL-Z-1 10 mM and etoposide 25 mM, respectively.
doi:10.1371/journal.pone.0112220.g005
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ssDNA present at stalled replication forks [36]. Both activated
kinases then phosphorylate and activate several downstream
effectors to arrest the cell cycle for DNA repair, including Chk1
and Chk2 (checkpoint kinases), which initiate a secondary wave of
phosphorylation events to extend signaling. Here, the data showed
that NPRL-Z-1induced DNA DSBs and increased phosphoryla-
tion of ATM and Chk2. Furthermore, ATM was reportedly
involved in regulating multiple cell cycle checkpoints (G1/S, S,
and G2/M phases) after DNA damage [37]. NPRL-Z-1 treatment
induced ATM phosphorylation at Ser 1981, which has been
shown to regulate ATM activity and p53 phosphorylation at Ser
15. In addition, DSBs triggered Chk2 phosphorylation at Thr 68
[38]. Activated Chk2 subsequently phosphorylated p53 at Ser 20
[39], which upregulated the expression of DNA-damage and cell
cycle arrest-related genes (p21 and p27) [40]. p21, a potent Cdk
inhibitor bound and inactivated cyclin E and the Cdk2 complex,
led to G1 cell cycle arrest through inhibition of Rb phosphory-
lation [41]. In addition, histone H2AX was required for p21-
induced cell cycle arrest after replication stalling [42]. The results
of this study showed that NPRL-Z-1 activated the ATM signaling
pathway and stimulated p53 accumulation, subsequently upregu-
lated the cell cycle regulators p21, p27 and cyclin E to cause G1
cell cycle arrest.
Many effective anticancer drugs target topoisomerases, includ-
ing etoposide. Previous research has demonstrated that etoposide
inhibited TOP2 activity by stabilizing a covalent TOP2–DNA
complex [12]. However, etoposide exhibits serious side effects,
drug-resistance, and poor water solubility, limiting its use.
Alternatively, NPRL-Z-1 was designed to enhance DNA TOP2
inhibition, overcome drug resistance, and increase water solubility
of etoposide analogues by extending the bulky substituent at C7.
The data from the present study revealed that NPRL-Z-1
inhibited the unwinding activity of TOP2, but not topoisomerase
I, by supercoiling of DNA, which likely led to replication inhibition
of A498 cells. Moreover, the relationship between TOP2
expression and drug sensitivity in tumor cells has been described
[43,44]. As shown in Fig. 1A, cytotoxicity was most potent in
A498 cells which may resulted from TOP2a and b expression
levels were higher than other cancer cell lines (Fig. S1 in File S1).
Furthermore, NPRL-Z-1 induced G1-phase arrest but etoposide
induced G2/M-phase arrest in A498 cells (Fig. S2 in File S1). Jin et
al. had found that tumor cells arrested in the G0/G1-phase of the
cell cycle are more susceptible to TRAIL-induced apoptosis
compared to cells arrested in other cell cycle phases [45]. They
found that caspase-9 inhibition can partially block the enhanced
TRAIL-induced apoptosis in G0/G1-arrested SW480 cells, but
not apoptosis in unsynchronized cells. These results suggested that
the mitochondrial pathway is more likely to be activated during
apoptosis when cells are arrested in G0/G1. Therefore, it
suggested that NRPL-Z-1 arrested cell cycle in G1 phase would
help for increasing drug sensitivity. In addition, we also found that
NPRL-Z-1 induced similar mechanism in ACHN cell (Fig. S3 in
File S1). Moreover, NPRL-Z-1 was 16-fold more potent than
etoposide in A498 and ACHN cells and may only 5-fold in A549
cell, suggesting NPRL-Z-1 had better efficacy than etoposide and
in renal carcinoma cell lines.
Many clinically useful anticancer drugs, including etoposide, m-
AMSA, doxorubicin, and mitoxantrone, act through a common
cytotoxic mechanism by inducing TOP2cc formation [18].
Etoposide induces TOP2cc formation and activates many
molecules in response to DNA damage, such as ATM, histone
H2AX, Chk1/2, p53, and replication protein A (RPA) [46-51],
which subsequently induce various cellular responses, including
cell cycle arrest, non-homologous end joining, homologous
recombination repair, and cell apoptosis [47,52–54]. Our results
revealed that NPRL-Z-1 induced TOP2cc formation in A498 cells
Figure 6. Effects of NPRL-Z-1 on TOP2cc formation in A498 cells. A498 cells were treated with NPRL-Z-1 or etoposide for 30 min and the ICE
assay was performed to detect TOP2–DNA adduct formation as described in Materials and Methods. TOP2-free form was partitioned into fractions
between 1 and 4. TOP2acc (A) and TOP2bcc (B) were trapped between fractions 5 and 8, respectively.
doi:10.1371/journal.pone.0112220.g006
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which indicated NPRL-Z-1 acted as a TOP2 poison. To validate
whether TOP2 was required for NPRL-Z-1-induced cell death, we
examined the effect of siRNA-mediated knockdown of TOP2a
and b. The results indicated that silencing of TOP2a and b
reversed NPRL-Z-1-induced cell apoptosis and DNA damage
signaling.
Previous reports had indicated that chemotherapeutic agents
may be selectively toxic to tumor cells because of increasing
oxidant stress due to excess of ROS [33,55,56]. In our study,
NPRL-Z-1 was shown to induce ROS accumulation and
significantly reversed by NAC, a precursor of glutathione (GSH).
In addition, NAC restored the cell viability and downregulation of
pro-caspase-3 and PARP cleavage after NPRL-Z-1 treatment in
A498 cells. It has been reported that GSH depletion is associated
with ROS generation and apoptosis induction [57,58]. Previous
studies have shown that etoposide could cause GSH depletion
[59,60]. Therefore, it suggested that ROS played a important role
in NPRL-Z-1-induced cell apoptosis pathway.
The PI3K/Akt signaling pathway plays a crucial role in
regulating cell proliferation, growth, apoptosis, survival, and
metabolism via phosphorylation of a variety of substrates, and
inhibition of Akt phosphorylation has been suggested as a novel
target for therapeutic agents in human cancer [61]. Sourbier et al.
showed that this pathway is constitutively activated in human
RCC and plays an essential role in RCC progression through the
inhibition of tumor cell apoptosis [62]. Horiguchi et al. [63]
evaluated Akt activation by immunohistochemistry in 48 human
renal cell carcinoma biopsies and investigated its association with
pathologic features and clinical outcome. They found that elevated
Akt activation could be a common finding, especially in high-
grade tumors and metastatic disease, and thus suggested that Akt
might have an important role in the pathogenesis and progression
of renal cell carcinoma. Here NPRL-Z-1 treatment markedly
Figure 7. Effects of TOP2 in NPRL-Z-1-induced cell death and DNA damage signaling. TOP2a or TOP2b siRNA was transfected to evaluate
expression of TOP2a (A) and TOP2b (B), cell viability using the MTT assay (C and D), expression of apoptosis-related proteins (PARP and pro-caspase-3)
(E and F) for 24 h, and DNA damage-related proteins (p-ATM, p53, and p-histone H2AX) (G and H) for 1 h in A498 cells. Data are expressed as the
mean percentage of control 6 S.D. of three independent experiments. *, & p,0.05, and **, ##, && p,0.01 compared with the treatment group. N3,
N10 and E25 indicated as NPRL-Z-1 3 mM, 10 mM and etoposide 25 mM, respectively.
doi:10.1371/journal.pone.0112220.g007
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suppressed the activation of Akt and related downstream proteins.
Therefore, we expected NPRL-Z-1 may be capable of preventing
tumor resistance and needed for further investigation.
In conclusion, NPRL-Z-1 induced DNA DSBs, TOP2cc
formation, and ROS production in A498 cells. When ATM was
activated by DSBs, p53 and p21 expression increased and cell
cycle was arrested. Ultimately, NPRL-Z-1 induced cell apoptosis.
Thus, these results provide compelling evidence that there is
potential for NPRL-Z-1 to be developed as a promising anticancer
drug.
Supporting Information
File S1 Supporting Figures. Figure S1. Expression of
TOP2a or TOP2b in A498, ACHN, and A549 cells. Three
human cancer cell lines (A498, ACHN, and A549) were seeded
overnight, harvested, and prepared for detection of TOP2a or
TOP2b expression via western blotting. Figure S2. Effects of
etoposide on cell cycle distribution in A498 cells. Cells
were incubated with vehicle or various concentrations of etoposide
for 24 h and detected cell cycle distribution by flow cytometry.
Figure S3. Effects of NPRL-Z-1 in ACNH cells. (A) NPRL-
Z-1 induced PARP cleavage. (B) NPRL-Z-1 induced DNA
checkpoints activation. (C) Transfection of siTOP2a or siTOP2b
could reverse NPRL-Z-1-induced cell death in ACHN cells.
(DOCX)
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